insiderbuyingselling Posted - 39 minutes ago

$NTRA new insider selling: 2393 shares. http://insiderbuyingselling.com/?t=NTRA

Agile_Mango_Penguin Posted - 2 days ago

$NTRA

insiderbuyingselling Posted - 2 days ago

$NTRA new insider selling: 787 shares. http://insiderbuyingselling.com/?t=NTRA

insiderbuyingselling Posted - 3 days ago

$NTRA new insider selling: 1523 shares. http://insiderbuyingselling.com/?t=NTRA

briefingcom Posted - 4 days ago

$NTRA: Natera announces significant milestone with 200+ peer-reviewed publications https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240422080509NTRA&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

Stock_Titan Posted - 4 days ago

$NTRA Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications https://www.stocktitan.net/news/NTRA/natera-announces-significant-milestone-with-200-peer-reviewed-6ffr602svmip.html

Listener2307 Posted - 1 week ago

$NTRA Not too happy about the price action lately, but it is just that - price action. Has very little to do with fundamental information. Do I dare buy Calls?.... Not yet, I think. The May 85s are around $6.

InsiderPeek Posted - 1 week ago

$NTRA CEO Chapman Steven Leonard sold 6.8k shares for $634.8k (ownership down 2.91%) insiderpeek.com/company/NTRA

insiderbuyingselling Posted - 1 week ago

$NTRA new insider selling: 6816 shares. http://insiderbuyingselling.com/?t=NTRA

Stocksrunner Posted - 1 week ago

$NTRA: Natera's target price rises by 7.38% to $102.96/share. Analysts remain bullish on its prospects. https://stocksrunner.com/symbol/NTRA

TipRanks Posted - 1 week ago

TipRanks’ ‘Perfect 10’ List: Analysts See Opportunity in These 2 Top-Scoring Stocks https://www.tipranks.com/news/article/tipranks-perfect-10-list-analysts-see-opportunity-in-these-2-top-scoring-stocks $GE $NTRA

Eliam Posted - 1 week ago

$NTRA got a 100 shares for starter at 90.14

erevnon Posted - 1 week ago

Goldman Sachs maintains Natera $NTRA at Buy and raises the price target from $90 to https://marketsblock.com/stock-upgrades-and-downgrades/

Wigglyick Posted - 2 weeks ago

@MaverikIT @DonCorleone77 @Im_not_Mr_Lebowski @IsabellaDC @net0trader @Cash4freedom @RonIsWrong $NTRA not yet, but I’m watching. Like it to come in more.

MaverikIT Posted - 2 weeks ago

@net0trader @DonCorleone77 @Wigglyick @RonIsWrong @IsabellaDC @Cash4freedom @Im_not_Mr_Lebowski Randy, $NTRA - into this yet ?

GuerillaStockTrading Posted - 2 weeks ago

Biotech is booming. Natera is leading the charge. See why analysts are all eyes on NTRA now. $NTRA https://www.guerillastocktrading.com/unveiling-natera-a-rising-star-in-molecular-diagnostics/

Listener2307 Posted - 2 weeks ago

$NTRA Showed $99 after hours on 4/11/2024. I sure am looking forward to a close above $100. Some of my shares were bought at $25. We have seen 100 and above once before; hopefully, this will be the last time we cross that milestone.

MaverikIT Posted - 2 weeks ago

@Wigglyick @DonCorleone77 @RonIsWrong @net0trader @Im_not_Mr_Lebowski @IsabellaDC @Cash4freedom Ok $NTRA

DonCorleone77 Posted - 2 weeks ago

$NTRA 2 of 2 - Natera announces publication of dd-cfDNA study data ....Multiple increased dd-cfDNA results were associated with lower eGFR, high immunological risk factors, and suspected ABMR in the absence of rejection on biopsy. These data further support the Prospera Kidney test's value as an early indicator of rejection vs biopsy. Real-world performance of the Prospera Kidney test to detect all forms of rejection in 249 patients with matched biopsy demonstrated an area under the curve of 0.88, showcasing performance consistent with prior validations.

DonCorleone77 Posted - 2 weeks ago

$NTRA 1 of 2 - Natera announces publication of dd-cfDNA study data Natera announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA, or dd-cfDNA, test as a leading indicator of kidney transplant rejection. The published manuscript can be found here. The ProActive study is the largest prospective dd-cfDNA study in kidney transplant recipients, with roughly 5,000 patients enrolled at 54 participating transplant centers. This published study included 1,631 patients with =18 months of follow-up data. Key findings include: dd-cfDNA levels were significantly elevated up to five months before biopsy-proven antibody-mediated acute rejection, or ABMR, and up to two months before biopsy-proven T cell-mediated rejection, or TCMR, compared to patients with a non-rejection biopsy. In contrast, serum creatinine levels were not significantly elevated at any time point before biopsy-proven TCMR or ABMR....

Stock_Titan Posted - 2 weeks ago

$NTRA Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation https://www.stocktitan.net/news/NTRA/natera-announces-publication-of-largest-prospective-dd-cf-dna-study-37mns63vcvin.html

briefingcom Posted - 2 weeks ago

$NTRA: Natera announces new data from two studies extending the clinical validation of its prospera heart dd-cfDNA test for heart transplant recipients https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240408080424NTRA&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

DonCorleone77 Posted - 2 weeks ago

$NTRA Natera assumed with a Buy at Craig-Hallum Craig-Hallum assumed coverage of Natera with a Buy rating and $117 price target. The firm acknowledges that the stock has had a huge run over the past six months and that the current valuation probably assumes upside to numbers and positive catalysts. Nonetheless, Craig-Hallum remains bullish as it believes Natera is an incredibly well-run company, there is still a huge runway for revenue growth for years to come, and there is potential for positive near-term catalysts and upside to numbers.

OpenOutcrier Posted - 2 weeks ago

$NTRA (+1.5% pre) Natera (NTRA) Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients - SI https://ooc.bz/l/29714

DonCorleone77 Posted - 2 weeks ago

$NTRA Natera announces new data from two studies on Prospera Heart dd-cfDNA test Natera announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasing the ability of the Prospera Heart donor-derived cfDNA test to detect rejection in adult and pediatric heart transplant recipients. These are the second and third peer-reviewed publications evaluating Natera's technology for use in heart transplantation. The DTRT-2 study, published recently in Pediatric Transplantation, was sponsored by the National Institutes of Health. A total of 487 samples from 160 heart transplant recipients were evaluated, of which 78 were pediatric and 82 were adult patients. The Prospera Heart test demonstrated outstanding performance in detecting rejection, as determined by histopathology from endomyocardial biopsies, with AUC of 0.82 in adult patients and 0.83 in pediatric patients. The study reported a negative predictive value of 92% for adult patients & 99% for pediatric patients...

Stock_Titan Posted - 2 weeks ago

$NTRA Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients https://www.stocktitan.net/news/NTRA/natera-announces-new-data-from-two-studies-extending-the-clinical-emf24xw5sy0u.html

tradingtwenty Posted - 3 weeks ago

$NTRA has trended 26 times in the past 24 hours (based on 5 minute intervals). Latest press release on Apr 05, 2024 07:00 AM: Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive... Link: https://tradingtwenty.com/news/419208/natera-announces-positive-surveillance-analysis-from-the-randomized-phase-iii-imvigor011-trial-in-muscle-invasive-bladder-cancer

MaverikIT Posted - 3 weeks ago

@net0trader @RonIsWrong @Wigglyick @Cash4freedom @Im_not_Mr_Lebowski @IsabellaDC @DonCorleone77 $NTRA - anyone needing testing ?

Cutlass Posted - 3 weeks ago

$NTRA Sweet Chart 📈 Natera Inc (NTRA) is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Stocksrunner Posted - 3 weeks ago

📈 Friday Analyst Upgrades: $NTRA upgraded at Bernstein on gross margin trajectory. $SOFI upgraded at KBW after year-to-date slump. $CNK double-upgraded at Wells Fargo on structurally better demand. https://stocksrunner.com/home